From July 1, 2023 to September 30, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 18,227,779 shares, representing 25.26% for $588.23 million under the buyback announced on November 5, 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.27 USD | -3.00% | -5.44% | +21.58% |
05-13 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
05-08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.58% | 2.11B | |
-4.22% | 12.11B | |
-4.87% | 8.07B | |
+4.91% | 5.67B | |
+27.42% | 5.48B | |
-9.89% | 4.12B | |
-58.99% | 2.75B | |
+8.97% | 2.62B | |
-4.26% | 2.33B | |
-6.23% | 1.83B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Tranche Update on Myriad Genetics, Inc.'s Equity Buyback Plan announced on November 5, 2013.